Cardiac Effects of Thyrotropin Oversuppression with Levothyroxine in Young Women with Differentiated Thyroid Cancer

Table 1

Baseline characteristics of differentiated thyroid cancer patients based on TNM classification and recurrence-risk stratification system.

Age	Thyroidectomy	Cell type	Remnant; ablation	TNM; system	Recurrence risk	LT4; dose; (μg/kg)	TSH; suppression; (year)	Comorbidity; (ongoing medication)
49	Total	Papillary	Yes	T4aN0M0	Intermediate	3.34	6	CML (imatinib)
36	Total	Papillary	No	T2N1aM0	Intermediate	2.20	8	None
54	Near-total	Papillary	Yes	T1bN0M0	Low	2.78	6	PMS (HT)
48	Total	Papillary	No	T2N1aM0	Intermediate	2.55	5	HTN (CCB)
33	Near-total	Hurthle	Yes	T1bN1aM0	Intermediate	2.66	6	None
38	Near-total	Papillary	Yes	T3N1bM0	Intermediate	2.80	6	None
38	Total	Papillary	Yes	T2N0M0	Low	2.79	9	None
50	Near-total	Papillary	Yes	T2N1aM0	Intermediate	3.05	6	None
41	Near-total	Papillary	Yes	T1aN1aM0	Intermediate	2.28	6	None
32	Total	Papillary	Yes	T2N0M0	Low	2.44	7	None
38	Total	Papillary	Yes	T2N1aM0	Intermediate	3.82	9	None
45	Total	Mixed	Yes	T2N0M0	Low	1.67	7	None
51	Near-total	Papillary	Yes	T2N1aM0	Intermediate	2.79	7	IDA (iron)
48	Total	Papillary	Yes	T1bN1aM0	Intermediate	3.62	9	PTB

CCB, calcium channel blocker; CML, chronic myeloid leukemia; HT, hormonal therapy; HTN, hypertension; IDA, iron deficiency anemia; LT4, levothyroxine; PMS, postmenopausal syndrome; PTB, pulmonary tuberculosis; TSH, thyroid-stimulating hormone.